Loading institutional data...
Loading institutional data...
Held by 1,593 of 5,944 reporting institutions (99th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $43.34 today, the market must believe free cash flow compounds 9.7%/yr for a decade (off $2.7B normalized FCF).
The market's 9.7% is more conservative than its 9-yr track record.
2-stage DCF · 1.48B shares · net debt -$1.7B
mean 10.5% · volatility σ 59% · implied rate exceeded in 5/8 yrs
Central path = implied 9.7%/yr growth; shaded band = ±1σ (59%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $3.7B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 12%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $2.0B covers the $250M due within a year 7.9× over. Scheduled principal only (excludes interest & revolver draws). As of 2011-03-31 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~116.7% on $299M of debt.
Cash of $2.0B fully covers short-term debt of $299M.
Mostly short-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-18
No material risks flagged.
Where each multiple sits in its own 14-yr range · 14th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.0× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 28.6 | 29.0 | 35.0 | 31.2 | 31.2 | 30.5 | 31.4 | 31.0 |
| Gross Profit | 71.4 | 71.0 | 65.0 | 68.8 | 68.8 | 69.5 | 68.6 | 69.0 |
| SG&A | 36.3 | 36.7 | 38.2 | 36.7 | 35.6 | 36.4 | 35.7 | 34.3 |
| Operating Income | 15.3 | 14.1 | -0.8 | 10.1 | 13.0 | 16.5 | 15.5 | 18.0 |
| Income Tax | -2.5 | -37.4 | 0.0 | 0.3 | 3.5 | 2.8 | 2.6 | 2.5 |
| Net Income | 17.0 | 43.8 | -0.8 | 8.8 | 5.5 | 11.2 | 11.0 | 14.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on BSX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.07B 100.0% | $16.75B 100.0% | $14.24B 100.0% | $12.68B 100.0% | $11.89B 100.0% | $9.91B 100.0% | $10.73B 100.0% | $9.82B 100.0% | $9.05B 100.0% | $9.08B 100.0% |
| Cost of Revenue | $6.22B 31.0% | $5.26B 31.4% | $4.34B 30.5% | $3.96B 31.2% | $3.71B 31.2% | $3.46B 35.0% | $3.12B 29.0% | $2.81B 28.6% | $2.59B 28.7% | $2.42B 26.7% |
| Gross Profit | $13.85B 69.0% | $11.49B 68.6% | $9.90B 69.5% | $8.73B 68.8% | $8.18B 68.8% | $6.45B 65.0% | $7.62B 71.0% | $7.01B 71.4% | $6.46B 71.3% | $5.96B 65.7% |
| Selling, General & Admin | $6.89B 34.3% | $5.98B 35.7% | $5.19B 36.4% | $4.52B 35.6% | $4.36B 36.7% | $3.79B 38.2% | $3.94B 36.7% | $3.57B 36.3% | $3.29B 36.4% | $3.10B 34.1% |
| Total Operating Expenses | $10.24B 51.0% | $8.89B 53.1% | $7.55B 53.0% | $7.08B 55.8% | $6.98B 58.7% | $6.53B 65.9% | $6.10B 56.8% | $5.50B 56.0% | $5.17B 57.1% | $5.51B 60.8% |
| Operating Income | $3.61B 18.0% | $2.60B 15.5% | $2.34B 16.5% | $1.65B 13.0% | $1.20B 10.1% | -$80.0M -0.8% | $1.52B 14.1% | $1.51B 15.3% | $1.28B 14.2% | $447.0M 4.9% |
| Interest Expense | $349.0M 1.7% | $305.0M 1.8% | $265.0M 1.9% | $470.0M 3.7% | $341.0M 2.9% | $361.0M 3.6% | $473.0M 4.4% | $241.0M 2.5% | $229.0M 2.5% | $233.0M 2.6% |
| Other Income (Expense), net | -$228.0M -1.1% | -$321.0M -1.9% | -$358.0M -2.5% | -$508.0M -4.0% | -$123.0M -1.0% | $1.0M 0.0% | -$831.0M -7.7% | -$85.0M -0.9% | -$353.0M -3.9% | -$270.0M -3.0% |
| Pretax Income | $3.38B 16.9% | $2.28B 13.6% | $1.99B 13.9% | $1.14B 9.0% | $1.08B 9.1% | -$79.0M -0.8% | $687.0M 6.4% | $1.42B 14.5% | $933.0M 10.3% | $177.0M 2.0% |
| Income Tax Expense | $493.0M 2.5% | $436.0M 2.6% | $393.0M 2.8% | $443.0M 3.5% | $36.0M 0.3% | $2.0M 0.0% | -$4.01B -37.4% | -$249.0M -2.5% | $828.0M 9.2% | -$170.0M -1.9% |
| Net Income | $2.89B 14.4% | $1.85B 11.0% | $1.59B 11.2% | $698.0M 5.5% | $1.04B 8.8% | -$82.0M -0.8% | $4.70B 43.8% | $1.67B 17.0% | $104.0M 1.1% | $347.0M 3.8% |
| Per Share | ||||||||||
| EPS (Basic) | $1.96 | $1.26 | $1.08 | $0.45 | $0.69 | $-0.08 | $3.38 | $1.21 | $0.08 | $0.26 |
| EPS (Diluted) | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | $-0.08 | $3.33 | $1.19 | $0.08 | $0.25 |
| Weighted Avg Shares (Basic) | 1.48B | 1.47B | 1.45B | 1.43B | 1.42B | 1.42B | 1.39B | 1.38B | 1.37B | 1.36B |
| Weighted Avg Shares (Diluted) | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B | 1.40B | 1.39B | 1.38B |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| BSX | $64.2B | 22.3× | 12.6× | 3.2× | 19.9% | 69.0% | 14.4% | 11.9% | 11.8% | 0.1× | 1,593 |
Peers = companies sharing BSX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.